Novartis Acquires Tourmaline Bio in $1.4B Deal to Strengthen Cardiovascular Portfolio

Published on LinkedIn (via Spencer Knight)

Novartis has announced its $1.4 billion acquisition of Tourmaline Bio, a New York–based biotech developing therapies for atherosclerotic cardiovascular disease. The deal, unanimously approved by both companies’ boards, centers on Pacibekitug, a Phase III–ready treatment targeting systemic inflammation in cardiovascular disease. Expected to close in Q4 2025, the acquisition positions Novartis to expand its cardiovascular pipeline with a wholly owned subsidiary and to reinforce leadership in addressing one of the world’s most pressing health burdens.

👉 Read the full article: Novartis Makes $1.4B Cardiovascular Acquisition

Disclaimer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.